header logo image


Page 16«..10..15161718..»

Archive for the ‘Neuropathy’ Category

Mar 4 | Spine Imaging and Intervention in Palm Springs | Palm Desert – Patch.com

Saturday, April 25th, 2020

Multiple disease categories will be covered during this 2 1/2-day course, which will focus on diagnosis, treatment, image-guided diagnostic and therapeutic procedures, indications for surgery, and evaluation of the post-operative patient.

At the conclusion of this activity, participants should be able to:

-Identify key imaging findings in spine trauma and other spine emergencies

-Understand imaging techniques and observations in peripheral neuropathy, vascular diseases of the spine and spinal cord lesions, spine infections and spine tumors.

-Describe degenerative changes in the spine and the radiologists role in diagnosis of spine conditions and pain management.

-Understand the basics of Regenerative Medicine

-Be familiar with advanced imaging techniques of the spine including diffusion imaging and fMRI.

-Know what the spine surgeon is looking for in the preoperative and postoperative imaging studies.

URLs:Website:https://go.evvnt.com/643445-0?...Tickets:https://go.evvnt.com/643445-1?...

Date and Time: On Thursday March 04, 2021 at 7:00 am (ends Saturday March 06, 2021 at 10:00 am)

Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education)

Prices:Practicing Physician/Industry: USD 1295.00,Military/Retired/Scientist/VA : USD 1195.00,Resident/Fellow/Technologist/PA/Nurse: USD 995.00

Speakers: Blake Johnson, MD, John Feller, MD, Adam Flanders, MD, Wende Gibbs, MD, David Polly, MD, Phillip Tirman, MD

Continue reading here:
Mar 4 | Spine Imaging and Intervention in Palm Springs | Palm Desert - Patch.com

Read More...

Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain – Yahoo…

Friday, April 17th, 2020

DOYLESTOWN, Pa., April 16, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Companys Chairman & CEO, Dean Petkanas, was featured in an OTCQB podcast discussing the cannabinoid therapeutics industry and its role in eradicating the current opioid epidemic.

In the podcast episode, Mr. Petkanas explained how the Companys patented leading drug candidate, KLS-13019, may reduce the use of opioids in the treatment of neuropathic pain. While opioids are considered the standard of care to treat neuropathic pain in the U.S., he spoke of the Companys promising research efforts and the recently published preclinical results showing that KLS-13019 may be a viable non-addictive, non-opioid option to prevent and reverse neuropathic pain. Additional research results have shown that KLS-13019 showed little to no inhibition to six known human opioid targets, whereas cannabidiol (CBD) did show marked and significant inhibition to the same opioid targets.

During the podcast, Mr. Petkanas also discussed Kannalifes original focus on oxidative stress-related diseases like overt hepatic encephalopathy (HE) and how the Company pivoted to chronic pain through a Phase 1 research grant from the National Institutes of Health National Institute on Drug Abuse (NIH-NIDA) to study KLS-13019 as a potential treatment for Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Were grateful for the opportunity to participate in OTC Markets podcast series and to have the ability to share our science and company with the public on the OTCQB, Mr. Petkanas said.

The Company recently completed the STTR phase 1 study funded by the grant from NIDA. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of CIPN.

About KLS-13019KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

About OTC Markets Group Inc.OTC Markets Group Inc. (OTCM) operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market for approximately 10,000 over-the-counter securities. Through OTC Link ATS and OTC Link ECN, OTCM connects a diverse network of broker-dealers that provide liquidity and execution services. OTCM enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors.

To learn more about how OTCM creates better informed and more efficient markets, visit http://www.otcmarkets.com.

Story continues

OTC Link ATS and OTC Link ECN are operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

Read more from the original source:
Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain - Yahoo...

Read More...

Diabetic Peripheral Neuropathy Treatment Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Surfacing Magazine

Friday, April 17th, 2020

A new research study has been presented by Industrygrowthinsights.com offering a comprehensive analysis on the Global Diabetic Peripheral Neuropathy Treatment Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Diabetic Peripheral Neuropathy Treatment Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Diabetic Peripheral Neuropathy Treatment Market Report with Latest Industry Trends @ https://industrygrowthinsights.com/request-sample/?reportId=186791

Major Players Covered in this Report are: Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Global Diabetic Peripheral Neuropathy Treatment Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:AntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

By Applications:HospitalClinicOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://industrygrowthinsights.com/ask-for-discount/?reportId=186791

Global Diabetic Peripheral Neuropathy Treatment Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Diabetic Peripheral Neuropathy Treatment on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Diabetic Peripheral Neuropathy Treatment sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Diabetic Peripheral Neuropathy Treatment sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=186791

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About Industrygrowthinsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, US.Phone No: US: +1 909 545 6473 | IND: +91-7000061386Email: sales@Industrygrowthinsights.comWebsite: https://Industrygrowthinsights.com

Read the original:
Diabetic Peripheral Neuropathy Treatment Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine

Read More...

Medical Foods Market to Witness Exponential Growth by 2025 – Science In Me

Friday, April 17th, 2020

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Original post:
Medical Foods Market to Witness Exponential Growth by 2025 - Science In Me

Read More...

Type 2 diabetes: The major warning in your feet due to blood sugar levels being too high – Express

Sunday, April 12th, 2020

Type 2 diabetes affects insulin in the body. Symptoms of type 2 diabetes include increased thirst, increased hunger, headaches and tiredness. Everybody needs insulin to live and has an essential job to help keep the body healthy. Insulin allows the glucose in the blood to enter the cells and fuel the body. When a person has type 2 diabetes, the body still breaks down carbohydrate from the food and drink and turns it into glucose.

The pancreas responds to this by releasing insulin, however, this insulin cant work properly, and blood sugar levels keep rising and more insulin is released.

This plays havoc on the body with various warning signs that the blood sugar levels are too high.

Left untreated, high blood sugar levels could cause strokes or heart attacks.

There is another side effect to ones health caused by high blood sugars and is knowns as neuropathy.

What is it?

For people with type 2 diabetes, foot complications such as neuropathy and circulation problems can make it difficult for wounds to heal.

Serious problems could arise and other foot issues such as calluses are also common in people with type 2 diabetes.

While calluses may not seem a big problem, left untrimmed they can turn into ulcers or open sores.

People with diabetes are also at risk for Charcot joint, a condition in which a weight-bearing joint progressively degenerates, and this could lead to bone loss or deformity in the feet.

The NHS said: Peripheral neuropathy develops when nerves in the bodys extremities, such as the feet, are damaged.

The symptoms depend on which nerves are affected. In the UK its estimated almost one in 10 people aged 55 or over are affected by peripheral neuropathy.

The main symptoms of neuropathy can include a numbness and tingling in the feet or hands, burning, stabbing or shooting pain in affected areas, loss of balance and co-ordination and muscle weakness, especially in the feet.

These symptoms are usually constant but may come and go.

Read the original here:
Type 2 diabetes: The major warning in your feet due to blood sugar levels being too high - Express

Read More...

First Case of COVID-19 Presenting as Guillain-Barr Reported – Medscape

Sunday, April 12th, 2020

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Physicians in China are reporting what they believe is the first case of COVID-19 initially presenting as acute Guillain-Barre syndrome (GBS). The patient was a 61-year-old woman returning home from Wuhan during the pandemic.

"GBS is an autoimmune neuropathy, which could be triggered by various infections," corresponding author Sheng Chen, MD, PhD, Shanghai Jiao Tong University School of Medicine, China, told Medscape Medical News.

However, "Our single case report only suggests a possible association between GBS and SARS-CoV-2 infection. It may or may not have a causal relationship," Chen noted.

The case study was published online April 1 in Lancet Neurology.

The female patient returned from Wuhan on January 19 but denied having any fever, cough, chest pain, or diarrhea. She presented on January 23 with acute weakness in both legs and severe fatigue that progressed.

At presentation, temperature was normal, oxygen saturation was 99% on room air, and the patient's respiratory rate was 16 breaths per minute. She was not tested for SARS-CoV-2 at that point.

A neurologic examination revealed symmetric weakness (Medical Research Council grade 4/5) and areflexia in both legs and feet. The patient's symptoms had progressed 3 days after admission, and testing revealed decreased sensation to light touch and pinprick.

Admission laboratory test results indicated a low lymphocyte count and thrombocytopenia. Results of nerve conduction studies performed on day 5 of hospitalization were consistent with demyelinating neuropathy.

She was diagnosed with GBS and given intravenous immunoglobulin. On day 8, she developed a dry cough and fever, and a chest CT showed ground-glass opacities in both lungs. At this point, she was tested for SARS-CoV-2, and the results were positive.

The patient was immediately transferred to an isolation room and received supportive care and antiviral drugs. Her condition improved gradually, and her lymphocyte and thrombocyte counts were normalon day 20.

At discharge on day 30, she had normal muscle strength in both arms and legs, and tendon reflexes in both legs and feet had returned. Her respiratory symptoms had resolved as well. A second SARS-CoV-2 test was negative.

Two relatives of the patient who had been with her during her hospital stay also tested positive for SARS-CoV-2 and were isolated and treated.

All of the hospital staff that cared for the patient, including two neurologists and six nurses, tested negative for SARS-CoV-2.

Given the temporal association, SARS-CoV-2 infection could be responsible for the development of GBS in this patient, the investigators note. They add that the onset of GBS symptoms overlapped with the period of SARS-CoV-2 infection.

"Hence Guillain-Barre syndrome associated with SARS-CoV-2 might follow the pattern of a parainfectious profile, instead of the classic postinfectious profile, as reported in Guillain-Barre syndrome associated with Zika virus," the researchers write.

"More cases with epidemiological data are necessary to support a causal relationship" between SARS-CoV-2 infection and GBS, said Chen.

"However, we still suggest physicians who encounter an acute GBS patient from a pandemic area protect themselves carefully and test [for the] virus on admission. If the result is positive, the patient needs to be isolated," Chen said.

Lancet Neurol. Published online April 1, 2020. Full text

For more Medscape Neurology news, join us on Facebook and Twitter.

More here:
First Case of COVID-19 Presenting as Guillain-Barr Reported - Medscape

Read More...

(2020-2025) Peripheral Neuropathy Treatment Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,…

Sunday, April 12th, 2020

Latest Report onPeripheral Neuropathy Treatment Market

The report titled Global Peripheral Neuropathy Treatment Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Peripheral Neuropathy Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Peripheral Neuropathy Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Peripheral Neuropathy Treatment market is carefully analyzed and researched about by the market analysts.

Peripheral Neuropathy Treatment Market competition by top manufacturers/ Key player Profiled: Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/689123

Global Peripheral Neuropathy Treatment Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Peripheral Neuropathy Treatment market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Peripheral Neuropathy Treatment Market Segment by Type covers: Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others

Peripheral Neuropathy Treatment Market Segment by Application covers:Platinum Agents, Taxanes, Vinca Alkaloids, Others

After reading the Peripheral Neuropathy Treatment market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Peripheral Neuropathy Treatment market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalPeripheral Neuropathy Treatment market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Peripheral Neuropathy Treatment market?What are the key factors driving the global Peripheral Neuropathy Treatment market size?Who are the key manufacturers in Peripheral Neuropathy Treatment market space?What are the market opportunities, market risk and market overview of the Peripheral Neuropathy Treatment market?What are sales, revenue, and price analysis of top manufacturers of Peripheral Neuropathy Treatment market?Who are the distributors, traders, and dealers of Peripheral Neuropathy Treatment market?What are the Peripheral Neuropathy Treatment market opportunities and threats faced by the vendors in the global Peripheral Neuropathy Treatment industries?What are sales, revenue, and price analysis by types and applications of Peripheral Neuropathy Treatment market?What are sales, revenue, and price analysis by regions of Peripheral Neuropathy Treatment industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/689123

Some of the Major Highlights of TOC covers:

Peripheral Neuropathy Treatment Regional Market Analysis

Peripheral Neuropathy Treatment Production by RegionsGlobal Peripheral Neuropathy Treatment Production by RegionsGlobal Peripheral Neuropathy Treatment Revenue by RegionsPeripheral Neuropathy Treatment Consumption by RegionsPeripheral Neuropathy Treatment Segment Market Analysis (by Type)

Global Peripheral Neuropathy Treatment Production by TypeGlobal Peripheral Neuropathy Treatment Revenue by TypePeripheral Neuropathy Treatment Price by TypePeripheral Neuropathy Treatment Segment Market Analysis (by Application)

Global Peripheral Neuropathy Treatment Consumption by ApplicationGlobal Peripheral Neuropathy Treatment Consumption Market Share by Application (2014-2020)Peripheral Neuropathy Treatment Major Manufacturers Analysis

Peripheral Neuropathy Treatment Production Sites and Area ServedProduct Introduction, Application and SpecificationPeripheral Neuropathy Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/689123

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the original post here:
(2020-2025) Peripheral Neuropathy Treatment Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,...

Read More...

Sensory loss can lead to isolation and depression – Thehour.com

Sunday, April 12th, 2020

Sensory loss can lead to isolation and depression

DOTHAN, Ala. (AP) Caring for a 101-year-old man whos deaf and almost totally blind takes patience and understanding.

Its the kind of work Nancy Griffin finds rewarding.

As one of the caregivers with Wiregrass Area Home Instead Senior Care looking after the man and his wife, Griffin sees the challenges people with sensory loss face.

She also recognizes that creating a supportive environment to help them live a fulfilling life is vital.

To see how they enjoy each other every day, it makes your heart smile, Griffin said.

A recent survey by Home Instead found that approximately 83% of U.S. adults 65 and older are living with at least one diminished sense.

Sensory impairments can lead to feelings of isolation and depression, and diminish a persons quality of life.

One of the things we see with these challenges or deprivations in senses is that a lot of people become withdrawn because they cant communicate, said Liz Woodard, a community service representative with Home Instead. They cant hear or they cant see so they tend to isolate and withdraw.

A decline in any of the five senses taste, smell, touch, hearing and sight can affect a persons well-being.

One in 5 adults 65 and older have partially lost their sense of taste, Woodard said. It leads to poor nutrition, loss of appetite, which also leads to decline in our seniors.

A diminished sense of smell can cause some seniors to eat too little or too much.

Damaged nerves, known as neuropathy, in the hands and feet can cause tingling, numbness, weakness and pain. The damage makes walking and other tasks difficult.

If somebody has diabetic neuropathy or neuropathy caused by something else, their ability to feel the floor could lead to injury from them knocking and hurting and injuring their feet, Woodard said.

Inner ear problems can affect hearing and balance. Impaired vision reduces a persons ability to perform daily tasks and move about unaided.

Because your depth perception is off you may not see your slippers that are right there on the floor and trip over them, or your little dog, Woodard said.

SOURCE OF HELP

Impaired senses and mobility can be debilitating for older adults. Southern Alabama Regional Council on Aging provides services to enhance the independence of seniors in Barbour, Coffee, Covington, Dale, Geneva, Henry and Houston counties.

Alicia Anderson, a long-term care ombudsman at SARCOA, said the organization offers age play training that can be geared toward nursing homes, groups and the public.

It kind of simulates the aging process, Anderson said. It goes over things like visual impairment, hearing loss, dementia.

The training helps people understand what its like to have diminished capabilities. The sessions are useful for anyone who deals with the elderly or disabled.

Griffin started working with the couple in 2017. The man and his wife, who will turn 95 in late May, were in the hospital with the flu and were about to be discharged.

Thats when the daughter contacted Home Instead, because they were both weak and needed 24-7 care, Griffin said.

Caregivers provide a variety of services that allow seniors to remain in their homes.

We help them bathe. We fix their meals. We keep their home clean, she said.

Griffin said being paired with the couple was a godsend because theyre like my grandparents.

She discovered right off the bat that the wife ran the house.

You have to respect that youre going into their home, Griffin said. You have to respect them. You cant go in and start rearranging furniture or telling them what theyre going to do. You dont do that. You go in, you respect them, and you do what they ask you to do.

Woodard said that approach is essential.

Were working with adults, not children, Woodard said.

Part of the job involves knowing what a client can and cannot do. Sensory-impairment kits let caregivers experience the challenges faced by people with sensory loss and other conditions, whether its opening a pill bottle or dealing with impaired vision.

Because the client cant hear and has poor vision, caregivers devised ways to communicate with him.

We have three of the white boards that we use a dry-erase marker on, Griffin said.

Questions can be answered with hand taps a tap on the back indicating yes and a tap on the wrist indicating no.

Every day, the man and his wife enjoy a game of Scrabble.

That is their time, every afternoon around 3 oclock before the 5 oclock news, Griffin said.

The news is the only time their television is turned on.

Otherwise were interacting with them on a daily basis, Griffin said.

The client loves paint-by-number.

To be 101, his hand is extremely steady, Griffin said. You know how tiny the spots are on a paint-by-number? He gets into those lines; he is so steady.

He also enjoys playing card and dice games.

He likes to play craps of all things, and he usually wins, Griffin said.

The man used to be a world traveler. He was a bachelor until age 54 when he married his wife, who had been married before.

We have watched several times his disc of his traveling out West, down South, up North, Griffin said. He has climbed mountains.

The couples optimism is inspiring. Griffin said they give me the best day that I can possibly have, honestly. I am constantly learning from them.

MULTIDIMENSIONAL JOB

Woodard said being a caregiver means looking after more than just the physical needs.

Its great that even with these challenges were still able to socially engage and to have some fun and to have some quality of life even with these challenges that our seniors face, she said.

Home Instead offers free resources and tools on its agingsenses.com website to help people understand the challenges of sensory loss. The website includes tips on things you can do to protect your senses and has an interactive video that lets you experience baking with vision loss.

Read the original:
Sensory loss can lead to isolation and depression - Thehour.com

Read More...

Coronavirus Outbreak: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Strategies and Insight Driven Transformation 2020-2025 – Curious Desk

Sunday, April 12th, 2020

Chemotherapy Induced Peripheral Neuropathy (CIPN) MarketLatest Research Report 2020:

The Chemotherapy Induced Peripheral Neuropathy (CIPN) report provides an independent information about the Chemotherapy Induced Peripheral Neuropathy (CIPN) industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report:Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Chemotherapy Induced Peripheral Neuropathy (CIPN) Market: Products in the Chemotherapy Induced Peripheral Neuropathy (CIPN) classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Company I, Company II, Company III, Company IV and more

Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Report Covers the Following Segments:

Segment by Type:Type I, Type II, Type III

Segment by Application:Application I, Application II, Application III

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Chemotherapy Induced Peripheral Neuropathy (CIPN) Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.

Market Forecast:Here, the report offers a complete forecast of the global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://brandessenceresearch.com/technology-media/global-antivirus-software-market-2018-2024

https://brandessenceresearch.com/agriculture/seed-treatment-fungicides-market-rising

https://brandessenceresearch.com/consumer-goods/global-steam-generator-irons-market-2014-2024

https://brandessenceresearch.com/consumer-goods/global-steam-generator-irons-market-2014-2024

https://www.marketwatch.com/press-release/speciality-chemicals-marketglobal-industry-analysis-size-share-growth-trends-and-forecast-20202025-2020-04-10

Read more:
Coronavirus Outbreak: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Strategies and Insight Driven Transformation 2020-2025 - Curious Desk

Read More...

Diabetic Neuropathy Drugs Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 – Jewish Life News

Sunday, April 12th, 2020

QY Research has recently curated a research report titled, Global Diabetic Neuropathy Drugs Market Research Report 2020. The report is structured on primary and secondary research methodologies that derive historic and forecast data. The global Diabetic Neuropathy Drugs market is growing remarkably fast and is likely to thrive in terms of volume and revenue during the forecast period. Readers can gain insight into the various opportunities and restraints shaping the market. The report demonstrates the progress and bends that will occur during the forecast period.

Global Diabetic Neuropathy Drugs Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2601446&source=atm

Competitive Landscape:

The analysts have provided a comprehensive analysis of the competitive landscape of the global Diabetic Neuropathy Drugs market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

The key players covered in this studyPfizerNovartisJohnson & JohnsonEli LillyGlaxoSmithKlineBoehringer IngelheimTeva PharmaceuticalDaiichi SankyoAstellas Pharma

Market segment by Type, the product can be split intoCalcium Channel Alpha-2 Delta LigandSNRIs and TCAsOthersMarket segment by Application, split intoHospitalsDrug StoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Diabetic Neuropathy Drugs status, future forecast, growth opportunity, key market and key players.To present the Diabetic Neuropathy Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Diabetic Neuropathy Drugs are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2601446&source=atm

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Global Diabetic Neuropathy Drugs Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Diabetic Neuropathy Drugs Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, China, and Japan alone. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2601446&licType=S&source=atm

See the rest here:
Diabetic Neuropathy Drugs Market Share, Growth by Top Company, Region, Applications, Drivers, Trends & Forecast to 2025 - Jewish Life News

Read More...

Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia – Neurology Advisor

Friday, March 20th, 2020

There is a close association between sarcopenia and diabetic peripheral neuropathy (DPN), according to study results published in Diabetes Research and Clinical Practice.

Sarcopenia may lead to reduced exercise and increased risk for microvascular complications in patients with diabetes mellitus, including nephropathy and retinopathy. Because there is little information on the association between sarcopenia and DPN, the goal of the current cross-sectional study was to explore this association. In addition, a cohort study was carried out to investigate the changes in muscle mass and nerve conduction velocity.

The cross-sectional study included 1794 individuals (937 men; mean age, 60.22 years). Of these, 183 patients (98 men; mean age, 59.08 years) were enrolled in the follow-up study with a median follow-up of 2.7 years.

All patients underwent nerve conduction tests and muscle mass index was calculated using the following formula: appendicular skeletal muscle mass (ASM; in kg) divided by height squared (HT2; in m2 [ASM/HT2]). The composite z scores for the sensory nerve conduction velocity (SCV) and motor nerve conduction velocity (MCV) were calculated. The changes in ASM/HT2, SCV, and MCV were calculated from the measurements approximately 2 years apart and changes in skeletal muscle were classified into 3 groups: a decrease in ASM/HT2 of >3%, a minor change within 3%, or an increase of >3%.

In men, the multivariate regression analysis showed that muscle mass index was positively associated with the median (=0.928; P <.001), ulnar (=1.462; P <.001), peroneal (=1.059; P =.001), and tibial MCV (=0.839; P =.001) among the motor neurons; the median (=1.499; P <.001), ulnar (=0.837; P =.044), peroneal (=2.090; P =.002), and sural SCV (=1.257; P =.014) among the sensory neurons; and the composite z scores of MCV (=0.197; P <.001) and SCV (=0.3000; P <.001).

Receiver operating characteristic analysis indicated that the optimal cutoff point for ASM/HT2 that indicated DPN was 7.09 kg/m2 (area under the curve, 0.605; 95% CI, 0.569-0.642; sensitivity, 53.1%; specificity, 72.3%).

No significant correlations were found between ASM/HT2 and MCV, SCV and neuropathy score, and DPN and sarcopenia in women.

In the follow-up cohort study, there was a strong positive association between 2-year changes in skeletal muscle and nerve conduction velocity. During the follow-up period, nerve conduction velocity increased in terms of the partial motor and sensory velocities with an increase in the muscle mass in men with diabetes. However, similar to the findings in the cross-sectional analysis, this phenomenon was generally not observed in women with diabetes.

The researchers noted several limitations to the study, including possible selection bias as the study was performed in a hospital and included mainly middle-aged adults with nonsevere diabetes. As such, the findings may not be generalizable to older patients.

The assessment of muscle mass may have clinical implications in the prevention of DPN in men with diabetes, concluded the researchers.

Reference

Zhang Y, Shen X, He L, Zhao F, Yan S. Association of sarcopenia and muscle mass with both peripheral neuropathy and nerve function in patients with type 2 diabetes [published online February 25, 2020]. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2020.108096

This article originally appeared on Endocrinology Advisor

View post:
Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia - Neurology Advisor

Read More...

Six Benefits Of Acupuncture For Cancer Patients – Long Island Weekly News

Friday, March 20th, 2020

By Elizabeth Martin

More than 39 percent of the population will be diagnosed with cancer at some point in their life, so chances are, someone you know has had cancer. A 2019 study in JAMA Oncology found that acupuncture was significantly associated with lower pain levels for cancer patients. It seems that recently Eastern medicine, such as acupuncture, is integrating with Western medicine. The ongoing opioid crisis makes it more challenging to address cancer pain management, making acupuncture an alternative for pain.

One of the common side effects of chemotherapy is neuropathy, where nerve damage causes tingling, numbness and other sensations that can be extremely uncomfortable. This pain is often not treated or cant be treated with pain medication, but acupuncture proves to be a great alternative. Acupuncture and Chinese Medicine help open the body up and heal by promoting the flow of Qi (our vital energy). Acupuncture helps to bring circulation and blood flow to certain areas, helping the body to heal itself.

As a practitioner, I hear over and over that cancer patients are apprehensive about taking another medication for the side effects of another medication. But acupuncture is a noninvasive way to treat these side effects. I already mentioned that acupuncture helps with neuropathy because it stimulates blood flow to the damaged nerves. With nausea and loss of appetite, acupuncturists can open up channels that lead to the stomach meridian to help the body work more efficiently and improve the flow of energy to that area.

When someone has insomnia, its a sign that the brain is not shutting off. Acupuncture tells the neurotransmitters in the brain to calm down and helps to reprogram your bodys own circadian rhythm. When we are working on patients with insomnia, most of the time we choose to work on the heart meridians, because the heart calms the mind, and in traditional Chinese medicine we believe it is connected to the mind and spirit.

Often, schedules are packed with doctors appointments, but a visit to the acupuncturist is one to look forward to. I wanted my office to feel like home, so I purposely designed my practice to be that way, touching on the five elements of Chinese Medicine: wood, water, fire, earth, and metal and making it a tranquil, medical spa-like atmosphere. Doctors often look at their patients like a number, rushing to get them in and out of the door, but during an acupuncture appointment at our practice, we make a point to spend the time to get to know our patients and help to talk them through the emotions they may be going through during their cancer diagnosis and treatment.

Elizabeth Martin

The theory is that acupuncture is compared to going for a runincreasing circulation, draining the lymph nodes, and releasing toxins. Whenever you get acupuncture, it releases neurotransmitters in the brain like serotonin and epinephrine, which helps boost energy levels and improve mood. At the practice we also use acupuncture to help treat allergies, as it goes back to my earlier point about opening the flow of Qi.

With the treatments and appointments that many cancer patients are already going to, they can often be afraid and apprehensive to try acupuncture while in treatment. But in fact, this is the best time to go. We often hear from our cancer patients that they felt overwhelmed with adding another appointment, but after coming to acupuncture they felt more relaxed, had less pain, and felt calmer after undergoing regular acupuncture treatments. Often the patients that were skeptical of acupuncture would take a break and very often when stopping acupuncture regularly, it caused their pain to return.

Acupuncture is only one pillar of Chinese Medicine, but other modalities include manual therapy, Chinese herbal medicine, and meditation practices like Qi gong. A recent meta-analysis in patients with cancer and insomnia showed that yoga, meditation, hypnosis, mindfulness-based stress reduction, and qi gong have a moderate effect on the improvement of sleep quality for up to three months. At my practice, we also do sound healing classes, which has been a great way to start meditation and can help reduce stress. This practice uses vibrations (vocal or instrumental-like gongs, Tibetan singing bowls and tuning forks) in order to relax your mind and body.

Elizabeth Martin is a board-certified licensed acupuncturist. She is the owner of Hands On Acupuncture and Massage Therapy PC on Long Island. Visit http://www.handsonacupuncture.com to learn more.

See the rest here:
Six Benefits Of Acupuncture For Cancer Patients - Long Island Weekly News

Read More...

Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 – Jewish Life News

Friday, March 20th, 2020

With having published myriads of reports, Diabetic Peripheral Neuropathy Treatment Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Diabetic Peripheral Neuropathy Treatment Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Diabetic Peripheral Neuropathy Treatment market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Diabetic Peripheral Neuropathy Treatment market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2251608&source=atm

The Diabetic Peripheral Neuropathy Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeAntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

Segment by ApplicationHospitalClinicOthers

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2251608&source=atm

What does the Diabetic Peripheral Neuropathy Treatment market report contain?

Readers can get the answers of the following questions while going through the Diabetic Peripheral Neuropathy Treatment market report:

And many more

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2251608&licType=S&source=atm

For More Information Kindly Contact:

ResearchMoz.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read more:
Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 - Jewish Life News

Read More...

Diabetic Neuropathy Market Application 2020 Industry Trends, Global Analysis, Business Growth & Demand, Top 5 Leading Players, Sectors &…

Friday, March 20th, 2020

Diabetic Neuropathy Market Research Report 2020, is mostly driven by the improved taking on of Diabetic Neuropathy across small and medium-sized enterprises. Worldwide Diabetic Neuropathy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetic Neuropathy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

About Diabetic Neuropathy Market Report

This research report categorizes the global Diabetic Neuropathy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2020-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Diabetic Neuropathy Market Report:

Diabetic Neuropathy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Diabetic Neuropathy, Market Driving Factor Analysis of Diabetic Neuropathy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Diabetic Neuropathy, and Cost and Gross Margin Analysis of Diabetic Neuropathy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Diabetic Neuropathy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Diabetic Neuropathy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Diabetic Neuropathy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Visit link:
Diabetic Neuropathy Market Application 2020 Industry Trends, Global Analysis, Business Growth & Demand, Top 5 Leading Players, Sectors &...

Read More...

Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders…

Friday, March 20th, 2020

DOYLESTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical med-chem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued Australian Patent AU2015204609B2 (the Patent) specific to Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy. This patent grant marks the seventh patent that Kannalife has received to date on a worldwide basis.

Under the Patent, Kannalife will further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

Australias pharma market is expected to reach $32.1 billion in 2020, according to data from research and consulting firm GlobalData.1

"We are pleased to see our IP estate recognized in Australia as novel and proprietary. We see this as an important first step towards commercializing our lead drug candidate KLS-13019 in that market in thefuture," said Dean Petkanas, CEO of Kannalife.

KLS-13019 leads Kannalifes intellectual property estate of novel, monotherapeutic molecules (KLS Family), which are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders.

Of the seven patents issued to Kannalife on this technology, two are U.S. patents and five are foreign patents claiming priority to Kannalifes original 2014 U.S. filing date through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy (the PCT Patent). The seven patents consist of AU2015204609B2, and the following six patents:

The Company recently completed a STTR phase 1 study funded by a grant from the National Institutes of Healths National Institute on Drug Abuse. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

Kannalife also has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.

About KLS-13019KLS-13019 is Kannalifes leading proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical med-chem company focused on the development of proprietary and patented novel monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Story continues

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References1. Drug Development & Deliver. Australias Pharma Sector to Grow to $32.1 Billionhttps://drug-dev.com/australias-pharma-sector-to-grow-to-32-1-billion/

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders...

Read More...

The Global Diabetic Neuropathy Treatment Market Anticipated to exhibit a CAGR 4.9% during Forecast Period 2018-2025. – Galus Australis

Monday, March 16th, 2020

The global Diabetic Neuropathy Treatment market research report initiates a comprehensive analysis of the global Diabetic Neuropathy Treatment market. It offers an in-depth analysis of the rate of development of the market in the estimated time period. Offering a brief outline, the report explores the influencing factors and size of the global Diabetic Neuropathy Treatment market in the estimated period. It also covers the major leading factors restraining the expansion of the global Diabetic Neuropathy Treatment market. The global Diabetic Neuropathy Treatment market research report emphasizes commanding players in the market linked with their market shares.

Get Access to the FREE sample report: https://digitsnmarkets.com/sample/4316-diabetic-neuropathy-treatment-market

The report offers helpful data that discloses the foremost players in the Diabetic Neuropathy Treatment market it also discusses the revenue division, business general idea, and product contributions of the key players in the market. The research study also analyzes the growth of the well-known market performers with the help of SWOT analysis. In addition, while evaluating the growth of main market players, the research report covers their recent business developments. Furthermore, various products and segments

Table of Content

Chapter 1: IntroductionChapter 2: Executive SummaryChapter 3: Market OverviewChapter 4: Diabetic Neuropathy Treatment Market, By TypeChapter 5: Diabetic Neuropathy Treatment Market, By DisorderChapter 6: Diabetic Neuropathy Treatment Market, By ApplicationChapter 7: Diabetic Neuropathy Treatment Market, By RegionChapter 8: Competition Landscape

The global Diabetic Neuropathy Treatment market is bifurcated on the basis various segments. The development of each segment is evaluated along with their predicted growth in the future. Reliable data and statistics are collected from the regulatory authorities to calculate the growth of various segments of the market. Additionally, the global Diabetic Neuropathy Treatment market is also divided on the basis of various regions such as the North America, and Europe, Asia Pacific, Latin America, and Middle East & Africa.

How This Report On Diabetic Neuropathy Treatment Market Can Help You?

About Digits N Markets:

Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.

Contact Us:

Digits N Markets410 E Santa Clara Street, Unit #762San Jose, CA 95113Phone :+1 408-622-0123Email: [emailprotected]Website:- http://www.digitsnmarkets.com

See more here:
The Global Diabetic Neuropathy Treatment Market Anticipated to exhibit a CAGR 4.9% during Forecast Period 2018-2025. - Galus Australis

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Current Analysis and Estimated Forecast to 2026 | Achelios Therapeutics Inc,…

Monday, March 16th, 2020

Index Markets Researchoffers a latest published report on the GlobalChemotherapy Induced Peripheral Neuropathy TreatmentMarket that contains data regarding CAGR forecasts and key parameters such as yearly market growth in order to have complete statistics about the future of the market worldwide. It also helps in showing the extensive scope that will open up for the market. The research encompasses various factors about the Chemotherapy Induced Peripheral Neuropathy Treatment market such as its popularity in the global market, segmentation, current trends that are being followed, technological advancements, and future forecasts. The report provides key statistics on market trends and advancements that can help the businesses operating in the industry to understand the market and strategize for their expansion accordingly.

Request for Sample Report @https://www.indexmarketsresearch.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-market-2/407461/#requestforsample

Global Chemotherapy Induced Peripheral Neuropathy Treatment market 2020-2026: Competitive AnalysisWe provide a detailed analysis of key players operating in the global Chemotherapy Induced Peripheral Neuropathy Treatment market, including key players such asAchelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc.

This comprehensive Chemotherapy Induced Peripheral Neuropathy Treatment Market research report includes a brief summary of the market considering the current and future scenarios. The report further illustrates detailed breakdown of the market region-wise and categorizes it at various levels. The report provides rival insights of key players in the business vertical followed by an overview of their different portfolios and growth strategies. An elaborative analysis of business vertical delivers a brief overview of the various segments that encompass this industry landscape. A detailed evaluation of the current market status has been described in this report study. Thorough analysis on the varied aspects like opportunities and restraints are provided in this report.

The Report can be Segmented as:Product Type Segmentation :APX-3330, BR-297, Cannabidiol, Dimiracetam, OthersIndustry Segmentation:Clinic, Hospital, Others

Region Coverage (Regional Production, Demand & Forecast by Countries etc.):* North America (U.S., Canada, Mexico)* Europe (Germany, U.K., France, Italy, Russia, Spain etc.)* Asia-Pacific (China, India, Japan, Southeast Asia etc.)* South America (Brazil, Argentina etc.)* Middle East & Africa (Saudi Arabia, South Africa etc.)

The report reviews the competitive landscape scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies. The research report is collated on the idea of historic and forecast data that will help the emerging market segments in making major business decisions. The Chemotherapy Induced Peripheral Neuropathy Treatment Market is one among the fastest-growing market and further explains the trajectory this market will absorb the forecast years. The main objective of this Chemotherapy Induced Peripheral Neuropathy Treatment research report is to define the size of the different segments and the geographies as well as to forecast the trends that are likely to gain traction in the following couple of years.

Reasons to Buy:* Obtain the most up to date information available on the Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Chemotherapy Induced Peripheral Neuropathy Treatment data.* Develop business strategies with the help of specific insights about the planned and announced Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Keep abreast of key new-build Chemotherapy Induced Peripheral Neuropathy Treatment projects globally.* Assess your competitors planned and Chemotherapy Induced Peripheral Neuropathy Treatment projects and capacities.

The report highlights the most recent market trends that are affecting the Chemotherapy Induced Peripheral Neuropathy Treatment market growth. It investigates the existing scenario of the global market, which takes into account several market dynamics with the combination of best industry insight, practical solutions, talent solutions and latest technology. To prepare this report, our analysts have used advanced primary and secondary research techniques and tools. The market contains the ability to become one of the most lucrative industries as factors related to this market such as divestments, launches, enhancements, partnerships, mergers, acquisitions, and other strategic initiatives by players in the Chemotherapy Induced Peripheral Neuropathy Treatment market.

Key Stakeholders1. Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers2. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors/Traders/Wholesalers3. Chemotherapy Induced Peripheral Neuropathy Treatment Subcomponent Manufacturers4. Industry Association5. Downstream Vendors

The Chemotherapy Induced Peripheral Neuropathy Treatment market report also mentions the consumption and supply as well as the export and import figures of the industry during the forecast period starting from 2015 to 2020. In addition, aspects such as the cost, revenue, gross margins, and price of Chemotherapy Induced Peripheral Neuropathy Treatment in the forecast horizon from 2015 to 2020 in terms of regions and countries. The forecast presented in the report evaluates the actual cost of the different types of Chemotherapy Induced Peripheral Neuropathy Treatment and the cost as per brands in the global Chemotherapy Induced Peripheral Neuropathy Treatment market over the forecast period. The report also covers segment data, including: type segment, industry segment, channel segment etc. cover different segment market size, both volume and value. Also cover different industries clients information, which is very important for the manufacturers.

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-market-2/407461/

The report provides key data points which includes important results and insights from our monitoring and analysis of the market for Chemotherapy Induced Peripheral Neuropathy Treatment industry. The report gives an analysis of important market events at regional and global levels. The report sheds light on current market trends, market dynamics, key opportunities and major challenges in the industry.

Request customize If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@indexmarketsresearch.com

Read the original post:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Current Analysis and Estimated Forecast to 2026 | Achelios Therapeutics Inc,...

Read More...

‘He’s an inmate’: Anguish mounts over virus-hit nursing home – RiverBender.com

Monday, March 16th, 2020

AP Mar 14, 2020 2 days ago

In this March 12, 2020, photo, Steve Sedlacek, right looks at his father, Chuck Sedlacek, back left, through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's brother Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

Flowers and other memorials are viewed Friday, March 13, 2020, near a sign at the entrance to the Life Care Center in Kirkland, Wash., near Seattle, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek poses for a photo while holding a photo of his father, Chuck, outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

A nurse works in the room of Chuck Sedlacek who has tested positive for the COVID-19 coronavirus Friday, March 13, 2020, as seen through the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's son Scott Sedlacek said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020 photo, Scott Sedlacek becomes animated as he holds a picture of his father, Chuck, and talks to reporters outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father who lives inside the center, and in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek, left, who has tested positive for the COVID-19 coronavirus, listens as Tim Killian, right, a spokesman for Life Care Center in Kirkland, Wash., answers one of Sedlacek's questions during Killian's daily press briefing. Sedlacek's father, Chuck, who also has tested positive, lives in the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek said he and his siblings have barely spoken to their father, who has blindness and neuropathy, and difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, a person is loaded into an ambulance at Life Care Center in Kirkland, Wash., which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 6, 2020, photo, Su Wilson, left, takes a photo with a worker at Life Care Center in Kirkland, Wash., after handing off flowers to give to her mother, June Liu, who lives at the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 6, 2020, photo, Su Wilson, front left, smiles after giving a worker at Life Care Center in Kirkland, Wash., flowers to give to her mother, June Liu, who lives at the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, right, who has tested positive for the COVID-19 coronavirus, wears a mask as he stands near reporters and listens to a spokesman for Life Care Center in Kirkland, Wash., during a daily press briefing. Sedlacek's father, Chuck, who also has tested positive, lives in the facility, which has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek said he and his siblings have barely spoken to their father, who has blindness and neuropathy, and difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

A nurse wearing a mask walks past the room of Chuck Sedlacek who has tested positive for the COVID-19 coronavirus Friday, March 13, 2020, as seen through the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek's son Scott Sedlacek said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, family members of Chuck Sedlacek, left, look at him through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek's son Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, left, who has tested positive for the coronavirus, wears a mask as he stands near reporters and listens to Tim Killian, right, a spokesman for Life Care Center in Kirkland, Wash., during Killian's daily briefing. Sedlacek's father Chuck, who also has tested positive, lives in the facility, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek becomes animated as talks to reporters outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father who lives inside the center, and in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, family members of Chuck Sedlacek wave and greet him through reflections in the window of his room at Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek's son Scott said that he and his siblings have barely spoken to their father inside the center, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 12, 2020, photo, Scott Sedlacek poses for a photo while holding a picture of his father, Chuck, outside Life Care Center in Kirkland, Wash., near Seattle. The facility has been at the center of the COVID-19 coronavirus outbreak in the state, and Sedlacek who also has tested positive for the virus said he and his siblings have barely spoken to their father, who in addition to testing positive for the coronavirus, has blindness, neuropathy, and has difficulty using a phone, saying he is more of an "inmate" than a patient. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

In this March 11, 2020, photo, Scott Sedlacek, left, who has tested positive for the coronavirus, wears a mask as he stands with his brother Steve outside the Life Care Center in Kirkland, Wash. Their father Chuck, who also has tested positive, lives in the facility, which has been at the center of the coronavirus outbreak in the state. Residents of assisted living facilities and their loved ones are facing a grim situation as the coronavirus spreads across the country, placing elderly people especially at risk. (AP Photo/Ted S. Warren)

KIRKLAND, Wash. (AP) Desperate to talk to their dad, Scott Sedlacek and his brother, Steve, stood outside his open nursing home window and shouted. They could barely hear his weak replies, but one came through clearly.

I feel like (expletive), the 86-year-old told them.

Chuck Sedlacek arrived at the Life Care Center of Kirkland three weeks ago for physical therapy, just before the suburban nursing home became the epicenter of the nation's worst coronavirus outbreak.

Now he's in worse shape than before.

Hes in isolation after contracting the virus, but his symptoms haven't progressed enough to warrant moving him to a hospital. He came seeking rehab for a broken ankle and banged-up knee after a fall, but he hasn't gotten out of bed in two weeks. Though he previously lived independently in a senior community where he could walk the halls and visit old friends, hes now losing his mobility from lack of exercise.

His five children have hardly spoken with him because his near blindness and neuropathy in his hands make it tough for him to use a phone. And, they say, the overwhelmed Life Care staff has given him just two sponge baths since he arrived.

Hes an inmate as much as he is a patient, said Scott Sedlacek, 64, who also caught the virus. We all love and really care about our dad, and we are absolutely scared. Loneliness kills a lot of people, too. We think this is a license for death.

The Sedlaceks experience is a grim tale of what residents and their loved ones face as the coronavirus spreads around the country and enters other long-term care facilities. While most people recover from the virus and many have mild symptoms, elderly residents are especially at risk.

The virus has been confirmed in at least 11 nursing homes or senior apartments in western Washington. A cluster has also emerged at a veterans home in Lebanon, Oregon, where eight cases were confirmed in recent days.

Nursing homes around the country which are frequently cited for infection control problems are on high alert for coronavirus, boosting their cleaning regimens and clamping down on visitors.

The families of the remaining Life Care residents have reason to be terrified. More than two dozen coronavirus deaths have been linked to the facility, and more than half of those inside have tested positive.

The residents remain in a purgatory. They are mostly restricted to their rooms with no visitors. Roommates or neighbors across the hall have vanished without explanation. Some people are confused about whats going on.

The families, meanwhile, say their anguish has been compounded by mixed messages and a lack of information.

The nurses have told the Sedlaceks they check their fathers temperature every four to eight hours, less often than the two hours promised by administrators. That's troubling, since the virus seems able to cause fevers to spike drastically in a short period. The family has no idea how or when theyll be able to transfer their father out of the center if he recovers from the virus.

Families also question why, long after the outbreak began in China, the U.S. health system was so ill-prepared to test for coronavirus that the facility was still admitting new patients, including Chuck Sedlacek, even after the first resident had been sent to the hospital with flu-like symptoms.

Life Care said there was no reason to think the cornavirus was present until it received news Feb. 29 that a resident had tested positive. Administrators said remaining workers one-third are out with virus symptoms are doing what they can to care for residents.

All I can say is the nurses share your frustration, spokesman Tim Killian told the Sedlaceks when they questioned him during a media availability outside the nursing home this week. We have diminished capability to take care of all the patients in the exact manner they need. ... We do need more help.

The inability to comfort confused parents has been especially painful.

June Lius family used to pick her up several times a week for home-cooked Taiwanese meals and church services. The 93-year-old, who doesnt speak English, has lived at Life Care for two years since a small stroke.

During a flu outbreak there last year, she was able to leave the facility to stay with her daughter, Su Wilson. But now shes stuck at the facility after developing a cough two weeks ago and testing positive for the virus. She doesn't understand why no one is coming to visit her and why she cant go stay with her family.

I think shes very, very depressed, not knowing whats going on, Wilson said. This is sad for a lot of families and for us. The staff are trying to do their best, but are you caring for their mental health, or is it just Isolation! Isolation! Check vitals! IV!?

Wilson has now taken to leaving homemade soup outside the nursing home for staff to bring inside to her mom.

There is hope that outbreaks at other nursing homes might be less severe as they adopt restrictions and learn from Life Cares experience.

For example, at the senior living community where Chuck Sedlacek typically lives, Emerald Heights in Redmond, a staff member at a skilled nursing facility developed symptoms early this month and immediately began staying home before a test confirmed the disease. Eleven residents deemed at risk were quickly isolated and tested; only one was positive.

Meanwhile, though, a resident of the separate independent living community has been confirmed to have the disease and is now in self-isolation.

Despite our advanced planning, were having to run very, very fast to stay ahead of this virus, said Kris Egskov, Aegis Living president, after a resident at Aegis Marymoor in Redmond, Washington, tested positive. We are preparing for the long-haul and accept that this may in fact be an entirely new paradigm in which to protect our residents.

Scott Sedlacek visited his dad four times before Life Care was locked down to visitors on Feb. 29. No one inside was even wearing face masks, he said.

On March 1, the sons joints began to ache. He spent two days trying to get tested for COVID-19, asking doctors as well as public health officials. Even though hed spent time at Life Care, the center of the worst U.S. outbreak, he couldnt obtain a test until after his fever spiked, he had trouble breathing and his wife brought him to a hospital emergency room, which cleared him of the flu and other illnesses.

He felt fine again within 12 hours of being treated with a bronchial nebulizer, and he quarantined himself until last Wednesday, when he cut the period short so he could visit his dad through the hospital window. He wore a yellow face mask as he yelled to him.

This is supposed to be my last day of quarantine, but being with my dad is way more important, Sedlacek said that night. Hes in there and hes lonely. The big thing we wanted to convey to him was, Were here for you, we love you and we want you to get better we just cant be in there with you.

___

Johnson reported from Seattle.

___

The Associated Press receives support for health and science coverage from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

___

Follow AP coverage of the virus outbreak at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Subscribe for FREE today.

We want to hear from you. Provide your thoughts and comments below.

The rest is here:
'He's an inmate': Anguish mounts over virus-hit nursing home - RiverBender.com

Read More...

Yorkshire Ripper Peter Sutcliffe struck down with condition that leaves him uncontrollably shaking – The Sun

Monday, March 16th, 2020

THE Yorkshire Ripper is suffering from a condition that leaves him with uncontrollable shaking.

Ailing Peter Sutcliffe, 73, has been diagnosed with diabetic neuropathy, causing tremors in his limbs.

2

It means the serial killer often shakes so badly he struggles to eat and to look after himself.

The progressive illness which is linked to overweight Sutcliffes diabetes is caused by high blood sugar levels and can result in nerve damage, numbness, pain and cramps.

In severe cases, sufferers cannot feel their limbs due to nerve damage. And it can lead to limbs, particularly feet, having to be amputated.

The Ripper, being held at Category A Frankland Prison, County Durham, is in poor general health and is given a daily cocktail of pills.

He has previously suffered a heart attack and angina.

Sutcliffe, who killed 13 women and attempted to murder seven more between 1975 and 1980, is waiting for an NHS operation to reduce the size of his prostate.

STAY HOMELondoners told to stay home as capital is worst hit by coronavirus

END THE EVENTSBoris Johnson says mass gatherings 'no longer supported' by government

Exclusive

CASHING INCoronavirus ghouls try to cash in on death with FAKE fundraising page for victim

Breaking

NEIGHBOUR BLOODBATHTwo women stabbed to death as man arrested for 'double murder'

TRAIL BLAZERWho is Jennifer Hosten and when did she win Miss World?

IN THE DOCKAlex Salmond alleged victim claims it was like 'wrestling an octopus'

He is also losing his eyesight, which medics have fought to save.

A source told The Sun on Sunday: Sutcliffe does not look a well man and his shakes are really noticeable. It is really bothering him.

This condition is one of the worst things you can get if youre diabetic particularly if youre fairly old and overweight.

2

View original post here:
Yorkshire Ripper Peter Sutcliffe struck down with condition that leaves him uncontrollably shaking - The Sun

Read More...

Intraoperative Neuromonitoring Market in the US 2020-2024 | Evolving Opportunities with Accurate Neuromonitoring LLC and Cadwell Industries Inc. |…

Monday, March 16th, 2020

The intraoperative neuromonitoring market in US is poised to grow by USD 955.33 million during 2020-2024, progressing at a CAGR of over 10% during the forecast period. Request free sample pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005573/en/

Technavio has announced its latest US research report titled Intraoperative Neuromonitoring Market in US 2020-2024 (Graphic: Business Wire)

Read the 120-page report with TOC on "Intraoperative Neuromonitoring Market In US Analysis Report by Type (Insourced IONM and Outsourced IONM), Application (Orthopedic and neurosurgeries, Cardiovascular surgeries, ENT surgeries, and Other surgeries), Methodology (Evoked potential (EP) monitoring, Electroencephalogram (EEG), and Electromyography (EMG), End-user (Hospitals, Ambulatory surgical centers (ASG), and Other end-users), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/intraoperative-neuromonitoring-market-in-us-industry-analysis

The market is driven by the increasing number of surgeries that require IONM. In addition, the rising adoption of remote IONM is anticipated to boost the growth of the intraoperative neuromonitoring market in the US.

The number of high-risk surgeries such as cardiovascular procedure, musculoskeletal, and spinal is increasing. Many people in the US, suffering from this condition experience severe long-term pain and disabilities. In addition, patients suffering from cervical or neck pain and lumbar or low back pain require medical attention. IONM are extensively used by surgeons because these medical conditions are often associated with neurological complications. For instance, surgeons use IONM while performing spine surgery because it allows the early identification of electrophysiologic changes. It is also used to identify hemodynamic and other abnormalities. Thus, the increasing number of surgeries that require IONM is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Intraoperative Neuromonitoring Companies in the US:

Accurate Neuromonitoring LLC

Accurate Neuromonitoring LLC operates the business under the Services segment. The company offers various services including motor strip mapping, cranial nerve monitoring, pedicle screw stimulations, and more. It also offers intraoperative neuromonitoring for performing neuro-surgical and other procedures.

Cadwell Industries Inc.

Cadwell Industries Inc. offers products through the following business units: EEG, EMG, IONM, Sleep, CADLINK, and Electrodes and accessories. The company offers Cascade IOMAX, Cascade PRO, Arc Alterna, and Arc Essentia.

Computational Diagnostics Inc.

Computational Diagnostics Inc. operates under various business segments, namely NeuroNet and Services. The company offers NeuroNet VII, NN600, and NN650. NN650 is a durable and easy to use IOM system, whereas, NN600 is a portable multi-modality capable system.

IntraNerve Neuroscience Holdings LC

IntraNerve Neuroscience Holdings LC offers products through the Services business segment. The company offers neuroscience services such as remote professional interpretation services, neurotelemetry/cEEG services, and intraoperative neuromonitoring services.

Medtronic Plc

Medtronic Plc offers products through the following business segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The company offers NIM-RESPONSE 3.0, BIS Complete 2-Channel Monitor, BIS Complete 4-Channel Monitor, and NIM-Neuro 3.0.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Intraoperative Neuromonitoring Market in US: Type Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: Application Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: Methodology Outlook (Revenue, USD Billion, 2020-2024)

Intraoperative Neuromonitoring Market in US: End-user Outlook (Revenue, USD Billion, 2020-2024)

Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Neurodiagnostic and Monitoring Devices Market Global Neurodiagnostic and Monitoring Devices Market by product (electroencephalograph (EEG) devices, intracranial pressure (ICP) devices, electromyography (EMG) devices, and others) and geography (Asia, Europe, North America, and ROW).

Diabetic Neuropathy Drugs Market Global Diabetic Neuropathy Drugs Market by action (calcium channel alpha-2-delta ligand, SNRIs and TCAs, and others) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005573/en/

Read more:
Intraoperative Neuromonitoring Market in the US 2020-2024 | Evolving Opportunities with Accurate Neuromonitoring LLC and Cadwell Industries Inc. |...

Read More...

Page 16«..10..15161718..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick